Tumor Metabolism as the Achilles' Heel in Prostate Cancer
Abstract
The hypothesis of this proposal was that the inhibition of monocarboxylate transporters (MCTs) can overcome resistance to enzalutamide in therapy-resistant prostate cancer cells. In advanced prostate cancer, glycolysis produces high levels of the toxic by-product lactate. Hence, prostate cancer cells upregulate the expression of MCTs to aid in lactate export. High levels of expression of MCTs have been associated with poor prognosis and biochemical failure in prostate cancer. Our findings so far show that the inhibition of MCT activity can suppress survival and proliferation of enzalutamide-resistant cells preferentially and can inhibit the growth of enzalutamide-resistant xenografts. In addition, we found that the combination of MCT inhibitors with enzalutamide reduced basal and compensatory glycolysis as well as extracellular acidification rates in enzalutamide-resistant prostate cancer cells. Once completed, our project may have an enormous impact on the future of prostate cancer research.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1149997
Entities
People
- Nagalakshmi Nadiminty
Organizations
- University of Toledo Health Science Campus